<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="12100">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00516919</url>
  </required_header>
  <id_info>
    <org_study_id>DF-06-018</org_study_id>
    <nct_id>NCT00516919</nct_id>
  </id_info>
  <brief_title>Study of Behavioral Weight Loss Therapy for Obesity and Binge Eating in Monolingual Hispanic Persons</brief_title>
  <official_title>Controlled Trial of Orlistat With Behavioral Weight Loss Therapy for Obesity and Binge Eating in Monolingual Hispanic Persons</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Donaghue Medical Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a research study designed to examine the effectiveness of an obesity medication
      (orlistat) given in addition to behavioral weight loss therapy. Participants will be obese
      monolingual (Spanish-speaking only) men and women.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2007</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Participant BMI</measure>
    <time_frame>4 months and 6 month follow-up</time_frame>
    <safety_issue>No</safety_issue>
    <description>Body Mass Index (BMI)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">79</enrollment>
  <condition>Obesity</condition>
  <condition>Binge Eating</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Xenical + behavioral intervention</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Placebo + behavioral intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Xenical + behavioral intervention</intervention_name>
    <description>120 mg TID; Behavioral weight loss in Spanish</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Xenical</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Behavioral intervention + placebo</intervention_name>
    <description>Behavioral weight loss treatment in Spanish Placebo TID</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Monolingual Spanish Speaking

          -  Obese (BMI &gt;= 30)

        Exclusion Criteria:

          -  Pregnancy

          -  Current cardiac disease

          -  Serious neurologic illnesses
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carlos M Grilo, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hispanic Clinic of the Connecticut Mental Health Center</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale Department of Psychiatry</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06519</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <lastchanged_date>January 7, 2013</lastchanged_date>
  <firstreceived_date>August 15, 2007</firstreceived_date>
  <firstreceived_results_date>July 31, 2012</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Yale University</investigator_affiliation>
    <investigator_full_name>Carlos Grilo</investigator_full_name>
    <investigator_title>Professor of Psychiatry and Psychology</investigator_title>
  </responsible_party>
  <keyword>Obesity</keyword>
  <keyword>Binge Eating</keyword>
  <keyword>Monolingual Hispanic Persons</keyword>
  <keyword>Orlistat</keyword>
  <keyword>Behavioral Weight Loss Treatment</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Binge-Eating Disorder</mesh_term>
    <mesh_term>Bulimia</mesh_term>
    <mesh_term>Bulimia Nervosa</mesh_term>
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Weight Loss</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Orlistat</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study enrolled participants from August 2007 through October 2009. Participants were a consecutive series of 79 monolingual (Spanish-speaking-only) obese Latino/as recruited from clinical teams and referrals at a community mental health center serving economically disadvantaged persons with mental health needs.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Xenical + Behavioral Intervention</title>
          <description>Drug: Xenical + Behavioral: behavioral intervention
Xenical + behavioral intervention : 120 mg three times a day; Behavioral weight loss in Spanish</description>
        </group>
        <group group_id="P2">
          <title>Placebo + Behavioral Intervention</title>
          <description>Drug: Placebo + Behavioral: behavioral intervention
Behavioral intervention + placebo : Behavioral weight loss treatment in Spanish Placebo three times a day</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="39"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Total Enrollment</title>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="79"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="79"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="46.3" spread="9.7"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="65"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="14"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="79"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Participant BMI</title>
        <description>Body Mass Index (BMI)</description>
        <time_frame>4 months and 6 month follow-up</time_frame>
        <safety_issue>No</safety_issue>
        <population>Data for all randomized participants were included. In the event of dropout or missing data, baseline values were used.</population>
        <group_list>
          <group group_id="O1">
            <title>Drug: Xenical + Behavioral: Behavioral Intervention</title>
            <description>Xenical + behavioral intervention
Xenical + behavioral intervention : 120 mg three times a day; Behavioral weight loss in Spanish</description>
          </group>
          <group group_id="O2">
            <title>Drug: Placebo + Behavioral: Behavioral Intervention</title>
            <description>Placebo + behavioral intervention
Behavioral intervention + placebo three times a day: Behavioral weight loss treatment in Spanish Placebo TID</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="40"/>
                  <measurement group_id="O2" value="39"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Participant BMI</title>
            <description>Body Mass Index (BMI)</description>
            <units>kg/m^2</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Post-treatment (4 months)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="36.0" spread="5.9"/>
                  <measurement group_id="O2" value="36.4" spread="4.7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>6 month follow up</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="36.3" spread="4.9"/>
                  <measurement group_id="O2" value="36.8" spread="4.7"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Test for group differences in BMI at post-treatment, controlling for baseline BMI.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>=0.51</p_value>
            <method>ANCOVA</method>
            <method_desc>Covariate = Baseline (pre-treatment) BMI; Degrees of freedom = (1, 76)</method_desc>
            <param_type>F statistic</param_type>
            <param_value>0.45</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Test for group differences in BMI at 6-month follow-up, controlling for baseline BMI.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>=0.41</p_value>
            <method>ANCOVA</method>
            <method_desc>Covariate = Baseline (pre-treatment) BMI; Degrees of freedom = (1, 76)</method_desc>
            <param_type>F statistic</param_type>
            <param_value>0.69</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data were collected for the duration of the trial (through 4 months of active treatment).</time_frame>
      <desc>Overall frequency of reported side effects was only slightly higher for Xenical than for placebo, although reports of minor gastrointestinal events known to be due to Xenical’s mechanism of action were higher for the Xenical condition. Nearly all events occurred early in treatment, were generally mild, and resolved spontaneously.</desc>
      <group_list>
        <group group_id="E1">
          <title>Drug: Xenical + Behavioral: Behavioral Intervention</title>
          <description>Xenical + behavioral intervention
Xenical + behavioral intervention : 120 mg three times a day; Behavioral weight loss in Spanish</description>
        </group>
        <group group_id="E2">
          <title>Drug: Placebo + Behaviora: Behavioral Intervention</title>
          <description>Placebo + behavioral intervention
Behavioral intervention + placebo three times a day: Behavioral weight loss treatment in Spanish Placebo TID</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Carlos Grilo</name_or_title>
      <organization>Yale University School of Medicine</organization>
      <phone>203-785-2792</phone>
      <email>carlos.grilo@yale.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
